Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive
loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA)
deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that
crosses the blood brain barrier, and also to the use of selective inhibitors of MAO-B, the
major DA metabolising enzyme in man.
Safinamide is an inhibitor of MAO-B. This is a phase III trial to evaluate the efficacy and
safety of safinamide (50 and 100 mg p.o. q.a.m.) compared to placebo as add-on therapy to a
stable dose to levodopa in subjects with advance idiopathic Parkinson's Disease.
The principal efficacy measure is the increase in mean daily "on" time during the 18-hr diary
recording period.